Oral Herombopag Olamine and subcutaneous recombinant human thrombopoietin after haploidentical hematopoietic stem cell transplantation

doi:10.12307/2024.733

Abstract

Abstract: BACKGROUND: Allogeneic hematopoietic stem cell transplantation is an important treatment for malignant hematological diseases, and delayed postoperative platelet implantation is a common complication that seriously affects the quality of patient survival; however, there are no standard protocols to improve platelet implantation rates and prevent platelet implantation delays.

OBJECTIVE: To compare the safety and efficacy of oral Herombopag Olamine versus subcutaneous recombinant human thrombopoietin for promoting platelet implantation in patients with malignant hematological diseases undergoing haploid hematopoietic stem cell transplantation.

METHODS: Clinical data of 163 patients with malignant hematological diseases who underwent haploidentical hematopoietic stem cell transplantation from January 2016 to October 2022 were retrospectively analyzed. A total of 72 patients who started to subcutaneously inject recombinant human thrombopoietin at +2 days were categorized into the recombinant human thrombopoietin group; a total of 27 patients who started to orally take Herombopag Olamine at +2 days were categorized into the Herombopag Olamine group; and 64 patients who did not apply Herombopag Olamine or recombinant human thrombopoietin were categorized into the blank control group. The implantation status, incidence of acute graft-versus-host disease of degree II-IV within 100 days, 1-year survival rate, 1-year recurrence rate, and safety were analyzed in the three groups.

RESULTS AND CONCLUSION: (1) The average follow-up time was 52(12-87) months. The implantation time of neutrophils in the blank control group, recombinant human thrombopoietin group, and Herombopag Olamine group was (12.95±3.88) days, (14.04±3.71) days, and (13.89±2.74) days, respectively, with no statistically significant difference (P=0.352); the implantation time of platelets was (15.16±6.27) days, (17.67±6.52) days, and (17.00±4.75) days, with no statistically significant difference (P=0.287). (2) The complete platelet implantation rate on day 60 was 64.06%, 90.28%, and 92.59%, respectively, and the difference was statistically significant (P < 0.001). The subgroup analysis showed that the difference between the blank control group and the recombinant human thrombopoietin group was statistically significant (P < 0.001), and the difference between the blank control group and the Herombopag Olamine group was statistically significant (P=0.004). The difference was not statistically significant between the recombinant human thrombopoietin group and Herombopag Olamine group (P=0.535). (3) 100-day II-IV degree acute graft-versus-host disease incidence in the blank control group, recombinant human thrombopoietin group, and Herombopag Olamine group were 25.00%, 30.56%, and 25.93%, respectively, and the difference was not statistically significant (P=0.752). (4) The incidence of cytomegalovirus anemia, cytomegalovirus pneumonia, and hepatic function injury had no statistical difference among the three groups (P > 0.05). (5) During the follow-up period, there was no thrombotic event in any of the three groups of patients. (6) The results showed that recombinant human thrombopoietin and Herombopag Olamine could improve the platelet implantation rate of malignant hematological disease patients after haploidentical hematopoietic stem cell transplantation, with comparable efficacy and good safety.

Key words: malignant hematological disease, haploidentical hematopoietic stem cell transplantation, Herombopag Olamine, recombinant human thrombopoietin, graft-versus-host disease, platelet implantation, implantation rate

CLC Number:

Kong Dai, Wang Xinkai, Zhang Wenhui, Pei Xiaohang, Lian Cheng, Niu Xiaona, Guo Honggang, Niu Junwei, Zhu Zunmin, Liu Zhongwen. Oral Herombopag Olamine and subcutaneous recombinant human thrombopoietin after haploidentical hematopoietic stem cell transplantation[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(1): 1-7.

Figures/Tables 3

References

[1] YAMAZAKI R, KUWANA M, MORI T, et al. Prolonged thrombocytopenia affer allogeneic hematopoiettc stem cell transplantatton: associattons with impaired platelet productton and increased platelet turnover. Bone Marrow Transplant. 2006;38(5):377-384.

[2] HUANG AJ, HU XX, WANG JM. Research Progress on Thrombocytopenia affer Allogeneic Hematopoiettc Stem Cell Transplantatton -Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017; 25(1):270-275.

[3] HUANG XJ. Current status of haploidenttcal stem cell transplantatton for leukemia. J Hematol Oncol. 2008;1:27.

[4] KANDA Y, CHIBA S, HIRAI H, et al. Allogeneic hematopoiettc stem cell transplantatton from family members other than HLA-identtcal siblings over the last decade (1991-2000). Blood. 2003;102(4): 1541-1547.

[5] KUZMINA Z, EDER S, BÖHM A, et al. Signiffcantly worse survival of pattents with NIH-deffned chronic graff-versus-host disease and thrombocytopenia or progressive onset type: results of a prospecttve study. Leukemia. 2012;26(4):746-756.

[6] ALEXANDER WS, ROBERTS AW, NICOLA NA, et al. Deffciencies in progenitor cells of multtple hematopoiettc lineages and defecttve megakaryocytopoiesis in mice lacking the thrombopoiettc receptor c-Mpl. Blood. 1996;87(6):2162-2170.

[7] HAN TT, XU LP, LIU DH, et al. Recombinant human thrombopoiettn promotes platelet engraffment affer haploidenttcal hematopoiettc stem cell transplantatton: a prospecttve randomized controlled trial. Ann Hematol. 2015;94(1):117-128.

[8] BUSSEL JB, SOFF G, BALDUZZI A, et al. A Review of Romiplosttm Mechanism of Actton and Clinical Applicability. Drug Des Devel Ther. 2021;15:2243-2268.

[9] WEN B, ZHANG X, CHEN S, et al. Oral eltrombopag versus subcutaneous recombinant human thrombopoiettn for promottng platelet engraffment affer allogeneic stem cell transplantatton: A prospecttve, non-inferiority, randomized controlled trial. Hematol Oncol. 2022;40(4):777-786.

[10] MEI H, LIU X, LI Y, et al. A multtcenter, randomized phase III trial of hetrombopag: a novel thrombopoiettn receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021; 14(1):37.

[11] ZHANG F, PENG G, HE G, et al. A Multtcenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efffcacy and Safety of Hetrombopag in Pattents with Severe Aplasttc Anemia (SAA). Blood. 2020;136:3-4.

[12] XIE C, ZHAO H, BAO X, et al. Pharmacological characterizatton of hetrombopag, a novel orally acttve human thrombopoiettn receptor agonist. J Cell Mol Med. 2018;22(11):5367-5377.

[13] 孔黛 , 陈香丽 , 裴晓杭 , 等 . 去除第 11 天甲氨蝶呤对单倍体造血干细胞移植患者发生急性移植物抗宿主病的影响 [J]. 中国组织工程研究 ,2022,26(31):5026-5031.

[14] SCHOEMANS HM, LEE SJ, FERRARA JL, et al. EBMT-NIH-CIBMTR Task Force positton statement on standardized terminology & guidance for graff-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401-1415.

[15] FORMAN SJ, NEGRIN RS, ANTIN JH, et al. Thomas’ Hematopoiettc Cell Transplantatton: Stem Cell Transplantatton[M]. 5th Ed. West Sussex, UK: John Wiley & Sons, Ltd. 2015:1012-1019.

[16] ALSHEMMARI S, AMEEN R, GAZIEV J. Haploidenttcal hematopoiettc stem-cell transplantatton in adults. Bone Marrow Res. 2011;2011: 303487.

[17] BLUMBERG N, HEAL JM, PHILLIPS GL, et al. Platelets--to transfuse or not to transfuse. Lancet. 2012;380(9850):1287-1289.

[18] ZHANG X, FU H, XU L, et al. Prolonged thrombocytopenia following allogeneic hematopoiettc stem cell transplantatton and its associatton with a reductton in ploidy and an immaturatton of megakaryocytes. Biol Blood Marrow Transplant. 2011;17(2):274-280.

[19] MARSH JC, MUFTI GJ. Eltrombopag: a stem cell cookie? Blood. 2014; 123(12):1774-1775.

[20] KUTER DJ. New thrombopoiettc growth factors. Blood. 2007;109(11): 4607-4616.

[21] COHN CS, BUSSEL JB. Romiplosttm: a second-generatton thrombopoiettn agonist. Drugs Today (Barc). 2009;45(3):175-188.

[22] KAPUR R, ASLAM R, SPECK ER, et al. Thrombopoiettn receptor agonist (TPO-RA) treatment raises platelet counts and reduces antt-platelet anttbody levels in mice with immune thrombocytopenia (ITP). Platelets. 2020;31(3):399-402.

[23] POLVERELLI N, CATANI L, SOLLAZZO D, et al. Platelet ffuctuattons during thrombopoiettn-receptor agonist treatment: correlatton with platelet apoptosis. Ann Hematol. 2015;94(2):339-341.

[24] CHINESE SOCIETY OF HEMATOLOGY, CHINESE MEDICAL ASSOCIATION. Chinese expert consensus on the management of hemorrhagic complicattons affer hematopoiettc stem cell transplantatton(2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42(4):276-280.

[25] AHMED S, BASHIR Q, BASSETT R, et al. Eltrombopag for PostTransplantatton Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021;27(5): 430.e1-430.e7.

[26] LIESVELD JL, PHILLIPS GL 2ND, BECKER M, et al. A phase 1 trial of eltrombopag in pattents undergoing stem cell transplantatton affer total body irradiatton. Biol Blood Marrow Transplant. 2013;19(12): 1745-1752.

[27] CATALÁ-LÓPEZ F, CORRALES I, DE LA FUENTE-HONRUBIA C, et al. Risk of thromboembolism with thrombopoiettn receptor agonists in adult pattents with thrombocytopenia: Systemattc review and metaanalysis of randomized controlled trials. Med Clin (Barc). 2015;145(12): 511-519.

[28] MITTELMAN M, PLATZBECKER U, AFANASYEV B, et al. Eltrombopag for advanced myelodysplasttc syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5(1):e34-e43.

[29] PEFFAULT DE LATOUR R, KULASEKARARAJ A, IACOBELLI S, et al. Eltrombopag Added to Immunosuppression in Severe Aplasttc Anemia. N Engl J Med. 2022;386(1):11-23.

[30] WOLFF SN, HERZIG R, LYNCH J, et al. Recombinant human thrombopoiettn (rhTPO) affer autologous bone marrow transplantatton: a phase I pharmacokinettc and pharmacodynamic study. Bone Marrow Transplant. 2001;27(3):261-268.

[31] ZHENG X, ZHANG H, GUO W, et al. Herombopag promotes platelet engraffment and decreases platelet transfusion affer allogeneic hematopoiettc stem cell transplantatton. Eur J Haematol. 2023;110(5):527-533.

[32] GHANIMA W, JUNKER P, HASSELBALCH HC, et al. Fibroproliferattve acttvity in pattents with immune thrombocytopenia (ITP) treated with thrombopoiettc agents. Br J Haematol. 2011;155(2):248-255.

[33] GHANIMA W, GEYER JT, LEE CS, et al. Bone marrow ffbrosis in 66 pattents with immune thrombocytopenia treated with thrombopoiettnreceptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937-944.

[34] MOUSTAFA I, FETOUH SM, BADAWY ME. Eltrombopag-Induced Myeloffbrosis in Pattents with Adult Immune Thrombocytopenia: Scoping Review. EMJ Hematol. 2019;7(1):69-79.

[35] GHANIMA W, COOPER N, RODEGHIERO F, et al. Thrombopoiettn receptor agonists: ten years later. Haematologica. 2019;104(6): 1112-1123.